News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
News
Business
BioCurex Inc. Signs Consent to Transfer Abbott Laboratories’s RECAF Licensing Agreement to General Electric Company
July 2, 2007
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
RICHMOND, British Columbia, July 2, 2007 (PRIME NEWSWIRE) -- BioCurex, Inc. (OTCBB:BOCX) announced today that, upon request from Abbott Labs, the Company has signed a document transferring Abbott's RECAF licensing agreement to General Electric (GE).
Twitter
LinkedIn
Facebook
Email
Print
Alliances
Abbott Laboratories
MORE ON THIS TOPIC
Manufacturing
Roche makes $300M China Production Promise After Multibillion US Investment
May 12, 2025
·
2 min read
·
Tristan Manalac
Legal
BMS, Sanofi Settle Plavix Suit With Hawaii for $700M
May 12, 2025
·
2 min read
·
Tristan Manalac
Layoffs
Insitro Cuts 22% of Workforce, Extending Runway Into 2027
May 9, 2025
·
2 min read
·
Angela Gabriel
Layoffs
Sanofi Cuts Off Antibody Partner, Forcing 80% Headcount Reduction at IGM
May 9, 2025
·
2 min read
·
Tristan Manalac